Sugi Predict

Sugi Predict / Compounds / SCHEMBL1059953

SCHEMBL1059953

SCHEMBL1059953

C[C@@H](C(=O)O)N(N=[N+]=[N-])c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.34
▸ PGR P06401 1/20 0.33
▸ ADRA2A P08913 1/20 0.33
▸ ADRA2B P18089 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ HRH1 P35367 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ KEAP1 Q14145 2/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ NFE2L2 Q16236 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ MMP2 P08253 1/20 0.32
▸ MMP9 P14780 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30847023 1.00 ALDH1A1 (0.36) ALDH1A1LMNATP53SMN1; SMN2NPSR1
SCHEMBL15155565 1.00 ALDH1A1 (0.36) ALDH1A1LMNATP53SMN1; SMN2NPSR1
SCHEMBL6077975 0.79 ALDH1A1 (0.43) ALDH1A1LMNATP53SMN1; SMN2NPSR1
SCHEMBL6077977 0.79 ALDH1A1 (0.43) ALDH1A1LMNATP53SMN1; SMN2NPSR1
SCHEMBL29268373 0.76 CPA3 (0.36) NPSR1
SCHEMBL22748981 0.73 NPC1 (0.38) ALDH1A1LMNATP53SMN1; SMN2NPSR1
SCHEMBL93387 0.70 PTGS2 (0.45) ALDH1A1LMNATP53SMN1; SMN2NPSR1
SCHEMBL157605 0.70 PTGS2 (0.45) ALDH1A1LMNATP53SMN1; SMN2NPSR1
SCHEMBL14463144 0.70 NPSR1 (0.44) ALDH1A1LMNATP53SMN1; SMN2NPSR1
SCHEMBL502831 0.70 PTGS2 (0.45) ALDH1A1LMNATP53SMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240408220-A1 PEPTIDE DENDRONS AND METHODS OF USE THEREOF ASTRAZENECA PHARMACEUTICALS LP 2024-12-12 — — US disclosed
EP-4412662-A1 PEPTIDE DENDRONS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2024-08-14 — — EP disclosed
EP-4350056-A2 GENETIC ENCODING OF CHEMICAL POST-TRANSLATIONAL MODIFICATION FOR PHAGE-DISPLAYED LIBRARIES The Governors Of The University Of Alberta (CA) 2024-04-10 — — EP disclosed
EP-3209819-B1 GENETIC ENCODING OF CHEMICAL POST-TRANSLATIONAL MODIFICATION FOR PHAGE-DISPLAYED LIBRARIES UNIV ALBERTA (CA) 2024-02-14 — — EP disclosed
WO-2023057975-A1 PEPTIDE DENDRONS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2023-04-13 — — WO disclosed
US-11542549-B2 Labeled enzyme compositions, methods and systems Life Technologies Corporation (US) 2023-01-03 — — US disclosed
US-11493503-B2 Method of quantifying peptide-derivative libraries using phage display 48Hour Discovery Inc. (CA) 2022-11-08 — — US disclosed
WO-2021146291-A1 SELF-ASSEMBLING PEPTIDE GEL FORMULATION AND METHODS OF USE Arch Biosurgery, Inc. (US) 2021-07-22 — — WO disclosed
US-11015220-B2 Conjugates of biomolecules to nanoparticles Life Technologies Corporation (US) 2021-05-25 — — US disclosed
US-10724034-B2 Genetic encoding of chemical post-translational modification for phage-displayed libraries 48Hour Discovery Inc. (CA) 2020-07-28 — — US disclosed
CN-104080479-A Carrier molecule comprising a spr0096 and a spr2021 antigen NOVARTIS AG 2014-10-01 — — CN disclosed
US-8741618-B2 Labeled enzyme compositions, methods and systems Life Technologies Corporation (US) 2014-06-03 — — US disclosed
US-8603792-B2 Conjugates of biomolecules to nanoparticles Life Technologies Corporation (US) 2013-12-10 — — US disclosed
WO-2013113127-A1 METHOD OF QUANTIFYING PEPTIDE-DERIVATIVE LIBRARIES USING PHAGE DISPLAY THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2013-08-08 — — WO disclosed
US-20130040363-A1 LABELED ENZYME COMPOSITIONS, METHODS AND SYSTEMS Life Technologies Corporation (US) 2013-02-14 — — US disclosed
WO-2010111691-A9 CONJUGATES OF BIOMOLECULES TO NANOPARTICLES LIFE TECHNOLOGIES CORP (US) 2011-01-06 — — WO disclosed
US-20110003343-A1 CONJUGATES OF BIOMOLECULES TO NANOPARTICLES Life Technologies Corporation (US) 2011-01-06 — — US disclosed
US-20100261185-A1 LABELED ENZYME COMPOSITIONS, METHODS AND SYSTEMS Life Technologies Corporation (US) 2010-10-14 — — US disclosed
WO-2010111686-A2 LABELED ENZYME COMPOSITIONS, METHODS & SYSTEMS LIFE TECHNOLOGIES CORP (US) 2010-09-30 — — WO disclosed
WO-2010111691-A2 CONJUGATES OF BIOMOLECULES TO NANOPARTICLES LIFE TECHNOLOGIES CORP (US) 2010-09-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11015220-B2 Conjugates of biomolecules to nanoparticles POLN, RNGTT, POLI ALDH1A1 506/4885LMNA 2186/4885TP53 1363/4885
US-11542549-B2 Labeled enzyme compositions, methods and systems RNGTT, DNTT, POLB ALDH1A1 483/4885LMNA 2051/4885TP53 1801/4885
US-20240408220-A1 PEPTIDE DENDRONS AND METHODS OF USE THEREOF VIP, NGLY1, PROKR1 ALDH1A1 3884/4885LMNA 1504/4885TP53 1640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.